本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Sun Life and charity partner join hands to bounce into the Chinese New Year and connect the community through joy Over 1,000 gift vouchers distributed in celebration of Sun Life's milestone as it looks ahead to its 135th anniversary in Hong Kong HONG KONG, Feb. 6, 2026 /PRNewswire/ -- The "Sun Life 'The Big Bounce' World Tour - Hong Kong" officially kicked off today at the Great Lawn of the Art Park in the West Kowloon Cultural District. Featuring the Guinness World Record-certified World's Biggest Bounce House, the event blends sports, music, and anime for a vibrant and joyful Chinese New Year celebration. As title sponsor, Sun Life invited hundreds of students and parents from Yan Chai Hospital-affiliated kindergartens and childcare centers to be among the first to enjoy the bouncing extravaganza. The ribbon-cutting ceremony at noon marked the official opening of the world's largest inflatable castle and a range of amusement facilities, kicking off 17 days of bouncing fun. The ceremony was officiated by Adley Low, Chief Client and Marketing Officer at Sun Life Hong Kong Limited and Jeffrey Li, Group President of INCUBASE Studio. Adley Low, Chief Client and Marketing Officer of Sun Life Hong Kong Limited, said: "As Sun Life approaches its 135th anniversary next year, we are delighted to see the community's enthusiasm for our flagship celebratory event, the "Sun Life 'The Big Bounce' World Tour – Hong Kong". Sun Life is committed to promoting health and wellbeing, and we firmly believe that nurturing the healthy development of young people is essential to enhancing community resilience. This event provides families with a joyful space to play together, and by inviting students and parents from Yan Chai Hospital's affiliated facilities to be the first to experience the fun, we hope to spread happiness across every corner of the community. We hope this event inspires the public to embrace a healthy and active lifestyle, leaping into the Chinese New Year with us, and bringing more vitality to society." Jason Leung, Chief Executive of Yan Chai Hospital Board, expressed his heartfelt gratitude to Sun Life: "Yan Chai is honored to receive the generous donation of tickets for this big event. It provides parents and children from Yan Chai's kindergartens with a great opportunity to enjoy quality family time together in this joyful environment, creating cherished childhood memories for our children." Furthermore, to celebrate Sun Life's upcoming 135th anniversary, starting on 9 February, the company is launching a series of online game activities on social media, giving away 1,350 vouchers to the public. For details, please refer to Sun Life's official social media channels. The "Sun Life 'The Big Bounce' World Tour – Hong Kong" runs from 6 to 22 February 2026 at the Great Lawn of the Art Park in the West Kowloon Cultural District. The event site covers over 100,000 square feet and features four mega inflatable play zones, including the World's Biggest Bounce House spanning over 16,000 square feet, certified by Guinness World Records; "The Giant", Hong Kong's longest inflatable obstacle course stretching over 150 meters; "Sport Slam", an arena for sports enthusiasts; and the outer-space themed "airSPACE Pink Alien". The event also offers dedicated daytime family sessions, "After Dark Bigger Kids" sessions, and CantoPop-themed "After Dark Party" sessions. About Sun Life Sun Life is a leading international financial services organisation providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including: Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, Mainland China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of September 30, 2025, Sun Life had total assets under management of $1.62 trillion. For more information, please visit www.sunlife.com. Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited (incorporated in Bermuda with limited liability) is a wholly-owned subsidiary of Sun Life Assurance Company of Canada and operates in Hong Kong.
SINGAPORE, Feb. 6, 2026 /PRNewswire/ -- Following the global success of its European and American editions, CYSAT Asia concluded its first-ever regional event in Singapore yesterday. Co-organised by SGInnovate and the European cybersecurity leader CYSEC, the event gathered 400 participants, global experts, government officials, and industry pioneers from 25 European and Asian countries to address the urgent need for resilient space infrastructure. The event convened leading voices from across the space tech and cybersecurity sectors to discuss the why's and how's of securing space assets, the impact of quantum computing on space cybersecurity, and the need for collaborative partnerships and strong talent pipelines to support this burgeoning industry. From investors to global corporations, key speakers at the event included representatives from Airbus, the European Commission, Fraunhofer, Institute of Electrical and Electronics Engineering, IonQ, IQT, and Thales, alongside Singaporean Deep Tech startups SpeQtral and MicroSec. Also present were industry stakeholders Infocomm Media Development Authority (IMDA), CyberSG R&D Programme Office (CRPO), and CyberSG Talent, Innovation and Growth (TIG) Collaboration Centre. "Through CYSAT Asia, we've extended that mission to one of the most consequential intersections in technology today: the confluence of space tech and cybersecurity", said Dr. Lim Jui, CEO, SGInnovate. "We're confident that the insights and connections shared today will catalyse innovation in this area, and lead to the development of more secure space infrastructure across the region." Panelists explore the intersection of quantum computing and satellite security at CYSAT Asia. (L-R): Emna Amri (CYSEC), Anna Beata Kalisz Hedegaard (Quantum Security Defence), Corey McClelland (IonQ), Prof. Michael Kasper (Fraunhofer Singapore), and Nicolas Pouymonbrat (IDQuantique). Exploring the landscape of space cyberthreats, and their impact on critical sectors Speakers underscored how attacks on space systems now have immediate, real-world consequences, from Global Navigation Satellite System (GNSS) spoofing disrupting thousands of commercial flights annually to cyber vulnerabilities in legacy satellite architectures never designed for today's threat environment. The event affirmed that resilience must be designed end-to-end — across satellites, ground stations, receivers, and the data flows that connect them. Beyond defence and commercial uses, panellists also emphasised that cybersecurity is now foundational to civil space services, where trust in data integrity and governance underpins safe use for disaster response, climate monitoring, and national planning. In his address, David Koh, Singapore's Commissioner of Cybersecurity and Chief Executive of the Cyber Security Agency of Singapore mentioned that there are rapid technological advancements accelerating the growth of the space industry, and emphasised that cybersecurity must now be "baked" into the design of these technologies to prevent disruptions with spillover effects across borders. Meanwhile, Jonathan Hung, Executive Director of the Office for Space Technology & Industry, Singapore (OSTIn), Singapore's national space office, emphasised that cyber resilience in space requires close coordination across government, industry, and the broader ecosystem. Strong cyber resilience underpins trust in space-enabled services, and is strengthened through robust multi-agency partnerships here in Singapore. Highlighting opportunities for growth and collaboration With the goal of raising awareness around space cybersecurity and laying important groundwork for the establishment of cross-industry collaboration, CYSAT Asia highlighted the critical role of public-private partnerships, international cooperation, and ecosystem-level investment. Hsien-Hui Tong, Executive Director of Investments at SGInnovate noted that although both space and cybersecurity are established sectors, their intersection remains under-invested, often failing between traditional commercial and sovereign funding models. Progress will depend on coordinated action – from governments acting as early anchor customers, to investors supporting deployment-ready solutions, and ecosystems enabling companies to test, integrate, and scale across borders. Building a pipeline of space cybersecurity talent The development of a long-term talent pipeline was also a key theme at the event. Experts likened a robust talent ecosystem to an iceberg: while certifications represent the visible tip, critical thinking and an adaptive mindset will be the critical factors underpinning success. They emphasised the need for a "Swiss Army Knife" skillsets, with multi-disciplinary abilities bridging the gap between IT and operational technology, and called for industry-vetted, hands-on training to prepare professionals for high-stakes environments. "Space systems today underpin critical national infrastructure, yet they remain a 'ticking cyber bomb' if we do not act collectively." quotes Patrick Trinkler, CEO of CYSEC. "CYSAT Asia 2026 has proven that securing these assets requires a diverse mix of talent — from cryptographers to mission operators — working outside of traditional silos to address the converging commercial, sovereign, and military stakes of 2030. Our goal is to ensure that as the space environment becomes more congested and contested, the integrity of our orbital data remains unassailable." To further bridge the gap between space tech and cybersecurity, CYSAT Asia hosted a series of technical keynotes and hands-on workshops, equipping industry professionals with knowledge at the intersection of space tech, cybersecurity, AI, and quantum computing. These workshops were part of the CYSAT Academy programme, an initiative designed to provide training and certifications in relevant, high-impact areas. At CYSAT Asia, the Academy ran two workshops: "Cyber Threats Along the Lifecycle of a Satellite" by HelvetiSpace, which dove into the threats faced by satellites at each stage of their lifecycle, typical challenges encountered across space systems, and other foundational concepts. "How to Hack a Satellite" by Thales, which educated participants on how to infiltrate satellite infrastructure, expanding their knowledge of attack surfaces and methods while exposing them to the impact of cyberattacks on satellites. Looking ahead to CYSAT Asia 2027, SGInnovate and CYSEC will continue to engage local and international ecosystems to bridge the gap between awareness and meaningful action, while building and bringing the community together to achieve true resiliency for space cybersecurity. Selected keynotes, technical sessions, and the event photo gallery are available for review. For more information and to access on-demand highlights, please visit: www.cysat.eu. About CYSEC CYSEC is a European cybersecurity company based in Switzerland and France, with additional locations in Italy and Luxembourg. The company provides world-leading, high-performance cybersecurity tools to ensure robustness, confidentiality, and integrity for the space internet networks & critical infrastructures. Since 2021, CYSEC has also been the organiser of CYSAT, the leading event in space cybersecurity in Europe, bringing together key industry players each year to discuss security challenges and implement solutions. About SGInnovate SGInnovate is a Deep Tech ecosystem builder and investor, backed by the Singapore Government. Our expertise and approach combines investments, talent development and community-building to catalyse the translation of emerging technologies into tomorrow's opportunities. Through our flagship Deep Tech Central platform, we connect individuals, founders and companies to specialised resources and opportunities across all technological domains and stages of growth. Our portfolio of emerging tech startups comprises some of the most promising companies leading the commercialisation of research developed from Singapore's RIE ecosystem. Connect with us at SGInnovate.com.
– Experience Edo Culture with All Five Senses through an Ukiyo-e Walking Tour, Woodblock Printing Workshop, and Artisan Studio Shopping – TOKYO, Feb. 6, 2026 /PRNewswire/ -- A new cultural tourism program titled "Ukiyo-e Guided Walking Tour + Woodblock Printing Experience and Artisan Studio Shopping" has been launched in the Mukojima area of Tokyo, offering visitors an immersive way to experience traditional Edo-period culture. This program combines the rich heritage of ukiyo-e art with contemporary craftsmanship, integrating a guided neighborhood walk, hands-on woodblock printing, and shopping at a traditional artisan studio into one comprehensive cultural experience. It is designed primarily for inbound international travelers as well as domestic visitors with a strong interest in Japanese culture. Located within walking distance of two of Tokyo's most popular destinations—Asakusa and Tokyo Skytree—the program offers a rare opportunity to enjoy a calm, historically preserved district where Edo-era atmosphere and living craftsmanship coexist. Tourism Media Service spoke with Sumida City Tourism Association about the new tourism resources originating from Tokyo's Mukojima. Mukojima developed along the eastern bank of the Sumida River during the Edo period and has long been known as a town of artisans. Even today, small independent workshops and family-run craft stores remain scattered throughout the neighborhood, producing items such as woodblock prints, folding screens, traditional paper, fittings, and decorative arts. Unlike large commercial tourist districts, Mukojima allows close interaction between visitors and craftspeople, offering direct access to production sites, tools, and techniques. This environment provides exceptional cultural value for travelers seeking authentic and meaningful experiences. The program fully leverages Mukojima's identity as a "living hub of traditional craftsmanship," guiding participants through a seamless flow of walking, learning, creating, and taking home their own artwork. The experience begins near Tokyo Skytree Station on the Tobu Skytree Line with a 60-minute guided walking tour along the historic Sumida River area. Participants visit scenic and culturally significant sites such as the former Hikifune Canal, Tokyo Mizumachi, Sumida Park, the Sumida River embankment, and Ushijima Shrine—locations that frequently appeared as motifs in classic ukiyo-e prints. The walk highlights the fusion of Edo-period landscapes with the modern urban environment. After the tour, participants move to a local workshop for a hands-on traditional woodblock printing experience. During the printing workshop, participants recreate the iconic image "The Great Wave" by world-renowned ukiyo-e master Katsushika Hokusai. This activity draws inspiration from the enduring global influence of Japonisme, the 19th-century movement that introduced Japanese art and aesthetics to Europe and continues to inspire admiration worldwide today. Guests may choose between traditional three-color or six-color printing methods, learning about pigment layering, washi paper textures, and classical printing techniques while completing their own artwork. Finished prints can be taken home as personal souvenirs, preserving the memory of the journey in tangible form. Afterward, visitors may browse and purchase handcrafted prints, washi products, and related artisanal goods at the adjoining studio shop, creating a fully integrated "Create, Learn, and Take Home" cultural experience. The meeting point and main venue for the program is Kataoka Byobu Shop, established in 1946 and recognized as the only specialty folding screen (byōbu) store in Tokyo. The shop manages the entire process from production to retail, preserving rare traditional techniques. Inside the Kataoka Byobu Gallery, visitors can view a wide variety of works including large gold folding screens, lavish gold-leaf decorated screens, modern art collaborations, and memorial screens created to commemorate special life events. The gallery showcases both classical elegance and contemporary innovation, allowing guests to witness the evolving nature of Japanese craftsmanship firsthand. The shop also accepts custom consultations for folding screen production, making it not only a viewing space but a living workshop where tradition continues to thrive. This program was developed to address challenges faced by traditional artisans, including declining demand and limited income opportunities. By linking tourism with cultural participation, it aims to support artisans' livelihoods while preserving and passing down traditional techniques. Through small-group, high-quality experiences, the initiative seeks to deepen cultural understanding while contributing to regional economic revitalization, positioning itself as a new model for sustainable cultural tourism in Tokyo. Contact InformationSumida City Tourism AssociationTEL: +81-3-5608-6951FAX: +81-3-5608-7130E-MAIL: e-fukazawa@visit-sumida.jp Contact Person: Eriko Fukazawa English language support is available. For pricing, schedules, and detailed program information, please contact the association directly. Reference InformationKataoka Byobu Shop – Official Websitehttps://www.byoubu.co.jp/ Experience Introduction Facebook Pagehttps://www.facebook.com/GoldenScreenArtisanCulture About Tourism Media Service:An online news platform specializing in the tourism industry. It provides the latest news on regional development and travel information, as well as feature articles on topics such as trends and observations, contributed by over 100 experts, every day.
KOTA KINABALU, Malaysia, Feb. 6, 2026 /PRNewswire/ -- The 3rd International Business Events Forum – BE in SABAH 2026 concluded today, marking the end of two days of structured engagement that brought together policymakers, industry leaders and practitioners to examine how Business Events can support regional cooperation, industry capability and economic connectivity across Asia Pacific. Hosted at the Sabah International Convention Centre, the forum recorded strong participation from both domestic and international stakeholders, underscoring growing interest in regional platforms that emphasise practical dialogue, professional standards and long-term collaboration. The official closing ceremony was officiated by Yang Berhormat Dr Andi MD Shamzureezal, Assistant Minister of Tourism, Culture and Environment Sabah, representing Yang Berhormat Datuk Jafry Bin Ariffin, Minister of Tourism, Culture and Environment Sabah and Patron of BE in SABAH 2026. In his closing remarks, Dr Andi noted that the discussions over the past two days highlighted the increasingly strategic role of Business Events in facilitating regional engagement, supporting industry professionalism and connecting markets through structured, outcome-driven platforms. He emphasised that continued collaboration across borders and sectors would be essential in strengthening resilience and competitiveness within the Asia Pacific Business Events ecosystem. Rather than centring on destination promotion, BE in SABAH 2026 was deliberately structured around issues affecting the industry at a regional and global level. Sessions addressed areas such as market confidence, governance, technology adoption, talent development and cross-border collaboration, reflecting the evolving expectations placed on Business Events as economic and professional infrastructure. The forum also facilitated knowledge exchange and partnership-building among participants from government agencies, international associations, convention bureaux, consulting firms and private sector organisations, reinforcing its role as a working platform that extends beyond dialogue. According to the Organising Chairperson, the value of BE in SABAH lies in continuity and relevance. "Each edition is designed to build on the last," she said. "The outcomes of this forum are measured not only by attendance, but by the quality of engagement, the relationships strengthened and the capability that continues to grow across the regional ecosystem." A key outcome of BE in SABAH 2026 is the strengthening of international collaboration, marked by the Memorandum of Understanding between the Goyang Convention & Visitors Bureau, Goyang International Expo and the Sabah International Convention Centre during the closing ceremony. The partnership reflects a shared commitment to collaboration beyond events, encompassing knowledge exchange, industry development and capacity-building, and builds on engagements initiated during Goyang Destination Week. Led by Dr Peter Lee, the participation of eight junior management representatives from Goyang at BE in SABAH 2026 further underscores a mutual focus on developing future industry leaders and strengthening professional capability through structured exposure and exchange. The collaboration signals ongoing efforts to deepen ties not only with South Korea, but also with other international destinations as part of a broader strategy to build a more connected, capable and resilient Business Events ecosystem. As BE in SABAH 2026 concludes, the forum reinforces its place as an annual Asia Pacific platform supporting sustained engagement, professional development and shared industry progress. The next edition will continue to build on this momentum, reflecting lessons learned and emerging priorities within the global Business Events landscape. ABOUT SICCSabah International Convention Centre (SICC) is owned by Innoprise Corporation Sdn Bhd of Yayasan Sabah Group – a state sanctioned organization in Sabah, Malaysia. SICC is the largest waterfront purpose-built convention, exhibition and entertainment facility in East Malaysia with a total function space of 153,197sqm. The gross built-up of the complex is 60,514sqm on a 6-hectare site. The multi-functional complex with its well-designed floor plan and extensive pre-function areas are well suited for a wide range of public and private events. For more information, please visit siccsabah.com or follow us on social media – LinkedIn, Facebook, Instagram and Twitter. About MACEOS Sabah ChapterThe Malaysian Association of Convention and Exhibition Organisers and Suppliers (MACEOS) Sabah Chapter represents the collective voice of Business Events organisers and suppliers in Sabah. It brings together industry practitioners across organising, venue services, logistics and event support to advance professional standards and strengthen collaboration within the Business Events ecosystem.
SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY® (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY® or placebo. The study results showed that, VELSIPITY® demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY® was consistent with previous studies, with no new safety signals observed. ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled global phase 3 pivotal studies, which further demonstrate the positive benefit-risk profile of VELSIPITY®. "Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally, "said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "The approval of VELSIPITY® underscores the clinical value of innovative therapies for UC and reflects Everest Medicines' sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options." "Ulcerative colitis is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system," said Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. "Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management. As a next-generation selective S1P receptor modulator, VELSIPITY® is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile, offering a new long-term treatment option for adults with moderately to severely active UC." "UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist," said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY®'s Asian clinical trial. "Results from the ENLIGHT UC study demonstrated that the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%[1]. As the first Phase 3 registrational study in Asian patients with moderately to severely active UC, the study confirms the efficacy and safety of VELSIPITY® in this population, with results published in The Lancet Gastroenterology & Hepatology[1]. Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management." UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031[2],[3]. Symptoms include mucous and bloody stools, abdominal pain, diarrhea and rectal tenesmus, all of which significantly impact patients' long-term quality of life. There remains a critical need for therapies that offer sustained and comprehensive disease control. "In China, a large population of patients with moderately to severely active UC continues to face substantial unmet medical needs," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "VELSIPITY® provides patients with moderately to severely active ulcerative colitis a once-daily oral therapy with the potential to achieve steroid-free remission and a favorable benefit–risk profile. Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing. We are committed to rapidly commercializing VELSIPITY® and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China." The clinical value of VELSIPITY® has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY® was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY® was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY® was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China. About VELSIPITY® (etrasimod arginine tablets) VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR and Mainland China for VELSIPITY® in ulcerative colitis, as well as in additional countries. About Phase 3 ENLIGHT UC Registrational study (ES101002) ENLIGHT is the largest Phase III trial of moderately to severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to receive etrasimod or placebo. Patients with an inadequate response or intolerance to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy were randomized to receive etrasimod once-daily or placebo for 12 weeks of induction treatment. Patients who completed the 12-week induction period and responded were re-randomized into the 40-week maintenance period to receive once-daily etrasimod or placebo. The primary efficacy endpoints were the proportion of patients achieving clinical remission at Week 12 (induction) and Week 40 (maintenance). The key secondary endpoints of the study were the proportion of patients achieving endoscopic improvement and clinical response at Week 12 (induction) and at Week 40 (maintenance). The study results showed that, during both the 12-week induction phase and the 40-week maintenance phase, etrasimod demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints. A significantly greater proportion of patients treated with etrasimod than those treated with placebo achieved clinical remission at induction Week 12 (57 [25.0%] of 228 patients vs 6 [5.4%] of 112 patients; adjusted difference 20.4%, 95% CI 13.4–27.4, p<0.0001) and at maintenance Week 40 (37 [48.1%] of 77 patients vs 10 [12.5%] of 80 patients; adjusted difference 35.9%, 95% CI 22.5–49.2, p<0.0001). At induction Week 12, a significantly greater proportion of patients treated with etrasimod than those treated with placebo showed endoscopic improvement (85 [37.3%] of 228 patients treated with etrasimod vs 11 [9.8%] of 112 patients treated with placebo; adjusted difference 28.6%, 95% CI 20.5–36.7, p<0·0001) and clinical response (133 [58.3%] of 228 patients treated with etrasimod vs 31 [27.7%] of 112 patients treated with placebo; adjusted difference 32.0%, 95% CI 21.8–42.2, p<0·0001). At maintenance Week 40, a significantly greater proportion of patients treated with etrasimod than those treated with placebo showed endoscopic improvement (47 [61.0%] of 77 patients treated with etrasimod vs 12 [15.0%] of 80 patients treated with placebo; adjusted difference 46.6%, 95% CI 33.2–60.1, p<0·0001) and clinical response (61 [79.2%] of 77 patients treated with etrasimod vs 28 [35.0%] of 80 patients treated with placebo; adjusted difference 45.6%, 95% CI 31.9–59.3, p<0·0001). Other secondary endpoints, including mucosal healing, endoscopic normalization, and histological remission, also significantly favored patients treated with etrasimod compared with placebo. Notably, mucosal healing as measured by a central read endoscopic subscore≤ 1 (excluding friability) with a Geboes Index score < 2.0, was achieved in 51.9% of the etrasimod treated patients compared to 8.8% in the placebo group (p<0.0001). The safety profile of etrasimod during the maintenance period was consistent with previous studies, with no new safety findings observed. About ELEVATE UC Phase 3 Registrational Program (ELEVATE UC 52 and ELEVATE UC 12) ELEVATE UC 52 and ELEVATE UC 12 are pivotal trials that are part of the ELEVATE UC Phase 3 registrational program[4]. ELEVATE UC 52 is a randomized, double-blind, placebo-controlled trial that utilized a treat-through design comprising a 12-week induction period followed by a 40-week maintenance period. Subjects were randomized to receive etrasimod or placebo and continued on treatment without re-randomization for the entire duration of the study. Beginning at Week 12, all patients could continue their randomized treatment; patients whose disease had not improved or had worsened compared with baseline could discontinue treatment and, if eligible, enroll in an open-label extension study. The primary objective of this trial was to assess the safety and efficacy of etrasimod 2 mg once daily on clinical remission after both 12 and 52 weeks. The primary endpoint was based on the 3-domain, modified Mayo score (MMS). In ELEVATE UC 52, clinical remission was achieved by 27.0% of patients receiving etrasimod compared with 7.0% of patients receiving placebo at Week 12 (19.8% differential, P˂0.0001) and by 32.0% compared with 7.0% at Week 52 (25.4% differential, P˂0.0001). Statistically significant improvements were observed in all key secondary endpoints, including endoscopic improvement and mucosal healing at Weeks 12 and 52, and corticosteroid-free remission and sustained clinical remission at Week 52. ELEVATE UC 12 is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of etrasimod 2 mg once daily in subjects with moderately to severely active UC. The primary objective of this trial was to assess the safety and efficacy of etrasimod on clinical remission at Week 12, as assessed by the 3-domain MMS. In ELEVATE UC 12, clinical remission was achieved among 25.0% of patients receiving etrasimod compared with 15.0% of patients receiving placebo (9.7% differential, P=0.026). All key secondary endpoints were met at Week 12, including endoscopic improvement and mucosal healing. In ELEVATE UC 12, a similar proportion of patients experienced treatment-emergent adverse events (AEs) between the etrasimod 2 mg and placebo treatment groups, while in ELEVATE UC 52, the proportion of adverse events was higher in the etrasimod 2 mg group compared with placebo. The proportion of patients experiencing serious AEs was similar between treatment groups in both trials. The most common treatment-emergent AEs occurring in 3% or more of etrasimod-treated patients and at a higher frequency than placebo through Week 52 in either trial were headache, elevated liver tests, worsening of UC, COVID-19 infection, dizziness, pyrexia, arthralgia, abdominal pain and nausea. Data support that initiation of etrasimod treatment does not require a complex up-titration regimen. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12, respectively, were naïve to biologic or JAK inhibitor therapy. References: [1]. K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. Full results of the ENLIGHT UC study (ES101002) by The Lancet Gastroenterology & Hepatology. [2]. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679. [3]. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. [4]. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
In Q4 of 2025, Coway's revenue reached KRW 1,275.4 billion (+13.3% YoY) with an operating profit of KRW 181.6 billion (-1.0% YoY) The company's FY2025 annual revenue totaled KRW 4,963.6 billion (+15.2% YoY) with an operating profit of KRW 878.7 billion (+10.5% YoY) Behind Coway's record growth in 2025 is the company's sleep and wellness brand BEREX, a new core revenue engine, as well as strong ice water purifier product sales SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ -- Coway Co., Ltd., the "Best Life Solution Company," has today announced its financial results for the fourth quarter and fiscal year 2025. Coway Financial Results "In the face of persistent global economic uncertainties, Coway was able to realize both top-line growth and profitability in 2025 by focusing on our fundamentals, strengthening our R&D capabilities and diversifying our product portfolio," stated Jangwon Seo, CEO of Coway. "Going forward, we will continue to maintain this stable momentum through product innovation across both our domestic and global markets." Coway's reported earnings are as follows: Fourth-quarter revenue: KRW 1,275.4 billion (+13.3% YoY) Fourth-quarter operating profit: KRW 181.6 billion (-1.0% YoY) Annual revenue: KRW 4,963.6 billion (+15.2% YoY) Annual operating profit: KRW 878.7 billion (+10.5% YoY) *The reported figures are taken from the consolidated K-IFRS (International Financial Reporting Standards) statement. The company's strong results across both domestic and global markets in 2025 were driven in no small part by the visionary mid- to long-term strategy previously introduced by Junhyuk Bang, Chairman of Netmarble and Coway, which includes launching innovative products, expanding into new business areas and strengthening the company's global footprint. Coway's domestic business reported an annual revenue of KRW 2,865.6 billion in 2025, marking an 11.0% year-over-year increase. This performance was bolstered, in particular, by strong sales in the ice water purifier category, as well as from the BEREX lineup of beds and massage chairs. Annual rental gross adds also saw impressive growth, increasing 7.7% year-over-year to a total of 1.85 million by the end of 2025. BEREX, the company's sleep and wellness brand, first launched as a key strategic initiative of Chairman Bang in December 2022, recorded a consolidated revenue of KRW 719.9 billion, thus firmly establishing itself as a key new revenue model for Coway. The brand's commercial success in 2025 was notably driven by the domestic bed business, which reached KRW 365.4 billion in revenue, up 15.4% compared to the previous year. Marking a 22.3% year-over-year increase, Coway's overseas subsidiaries contributed KRW 1,889.9 billion in annual revenue in 2025. The company's Malaysian subsidiary maintained its market leadership with a revenue of KRW 1,409.5 billion (+21.7% YoY), while the United States subsidiary saw a 10.5% year-over-year increase in its annual revenue, reaching KRW 236.7 billion. Furthermore, Coway's Thailand and Indonesia subsidiaries also achieved rapid growth, with impressive year-over-year increases of 38.8% and 67.5% and annual revenue totals of KRW 174.4 billion and 50.6 billion, respectively. For additional details about Coway's financial performance, please visit the company's Investor Relations page. About Coway Co., Ltd. Established in Korea in 1989, Coway, the "Best Life Solution Company," is a leading home environment appliances company making people's lives healthy and comfortable with innovative home appliances such as water purifiers, air purifiers, bidets, and mattresses. BEREX, the company's sleep & wellness brand, aims to improve the quality of life through cutting-edge mattresses and massage chairs. Since being founded, Coway has become a leader in the home environment appliances industry, with intensive research, engineering, development, and customer service. The company has proven dedication to innovation with award-winning products, home health expertise, unrivaled market share, customer satisfaction, and brand recognition. Coway continues to innovate by diversifying product lines and accelerating overseas business in Malaysia, the USA, Thailand, China, Indonesia, Vietnam, and Europe, based on the business success in Korea. In 2025, the company launched Coway Life Solution, a premium elder care platform offering personalized care solutions tailored to different life stages. For more information, please visit http://www.coway.com/ or http://newsroom.coway.com.
A12 藝術空間
environment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
